Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

1 total trials 1 recruiting

Filter these 1 trials by phase, country, sponsor and more.

Open in Search →

Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting

2023-505616-38-00 4 2024-09-04

Showing 1–1 of 1 trials